Animal Testing: A Necessary Evil for Medical Breakthroughs
As scientists push to develop alternative methods to replace animal testing in research, it's becoming increasingly clear that abandoning this practice altogether may not be the best course of action. Dr. Robin Lovell-Badge and Prof Emma Robinson argue that while new approach methodologies (NAMs) show promise, they are still limited by their reliance on animal-derived products.
Currently, many NAMs, such as organoids and organs-on-a-chip, rely on a crucial growing matrix called matrigel, which is derived from mouse sarcoma tumors. These technologies also often require foetal bovine serum, containing essential growth factors that synthetic alternatives cannot currently replace.
While increased investment in NAMs may help identify and develop alternative products, it's unrealistic to expect these alternatives to emerge quickly enough to completely replace animal testing. Biology is complex, and understanding the intricacies of complex diseases such as developmental changes, aging, or interactions between biology and environment will likely require further research involving living organisms.
Moreover, premature abandonment of animal testing could demotivate highly skilled and well-trained animal technologists who are crucial to many studies. The loss of these experts would affect not only the UK's competitiveness but also the wellbeing of animals in research.
The authors suggest that aspects of NAMs could be sped up for simpler assays such as toxicity and pharmacokinetics, where regulations already require animal testing. However, even with advancements in NAMs, it's likely that some areas of science will remain reliant on animal testing for years to come.
Ultimately, finding a balance between the use of animals in research and the development of alternative methods is key. Strict regulation and continued investment in NAMs may be necessary to drive progress towards an animal-free future while ensuring that medical breakthroughs continue to emerge.
As scientists push to develop alternative methods to replace animal testing in research, it's becoming increasingly clear that abandoning this practice altogether may not be the best course of action. Dr. Robin Lovell-Badge and Prof Emma Robinson argue that while new approach methodologies (NAMs) show promise, they are still limited by their reliance on animal-derived products.
Currently, many NAMs, such as organoids and organs-on-a-chip, rely on a crucial growing matrix called matrigel, which is derived from mouse sarcoma tumors. These technologies also often require foetal bovine serum, containing essential growth factors that synthetic alternatives cannot currently replace.
While increased investment in NAMs may help identify and develop alternative products, it's unrealistic to expect these alternatives to emerge quickly enough to completely replace animal testing. Biology is complex, and understanding the intricacies of complex diseases such as developmental changes, aging, or interactions between biology and environment will likely require further research involving living organisms.
Moreover, premature abandonment of animal testing could demotivate highly skilled and well-trained animal technologists who are crucial to many studies. The loss of these experts would affect not only the UK's competitiveness but also the wellbeing of animals in research.
The authors suggest that aspects of NAMs could be sped up for simpler assays such as toxicity and pharmacokinetics, where regulations already require animal testing. However, even with advancements in NAMs, it's likely that some areas of science will remain reliant on animal testing for years to come.
Ultimately, finding a balance between the use of animals in research and the development of alternative methods is key. Strict regulation and continued investment in NAMs may be necessary to drive progress towards an animal-free future while ensuring that medical breakthroughs continue to emerge.